Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Over 1,000 Irish people potentially affected by valproate syndrome

By Catherine Reilly - 13th Mar 2019 | 23 views

A HSE-commissioned report estimates that up to 1,250 children have experienced some form of neurodevelopmental delay and between 153 and 341 children a major congenital malformation arising from sodium valproate exposure in utero from 1975 to 2015. Rapid assessment of the number of women and children exposed to sodium valproate in Ireland 1975-2015 said the data was subject to many assumptions.

In Ireland, sodium valproate (Epilim) is licensed for epilepsy and bipolar disorder. Babies born to women who take valproate-containing medicines during pregnancy have up to a 40 per cent risk of developmental disability and 10 per cent risk of birth defects.

In February 2018, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee found that women were not always receiving appropriate and timely information on risks, despite previous measures announced in 2014.

As part of EMA measures issued in May 2018, sodium valproate must not be used in women able to have children unless the conditions of a pregnancy prevention programme are met.

A recent paper in BMJ Evidence-Based Medicine by researchers from the University of Oxford stated that such measures “should have been instituted several years ago, as the evidence was clear as far back as 1990 that there were risks of congenital malformations in women exposed to valproate”. 

Last May, the Oireachtas Health Committee recommended establishing an independent investigation into use of the drug and further consideration of the compensation issue.

According to the Department of Health, the Minister has not ruled out an independent inquiry.

A spokesperson for Sanofi, makers of Epilim, said it “has provided information and warnings” on its sodium valproate products, including use during pregnancy, “in accordance with regulatory requirements.” The spokesperson said information was approved by the Health Products Regulatory Authority as consistent with contemporaneous scientific and medical knowledge before it was put into circulation.  “In these circumstances, we do not believe there is any basis for compensation by the company.”

The State Claims Agency has been notified by a legal firm regarding a case on sodium valproate but has not received any claims to date.  

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read